Dr. Mark Blaskovich is a Senior Research Officer at the University of Queensland.
He has extensive medicinal chemistry expertise resulting from more than 16 years of industrial drug development experience.
As Chief Operating Officer at Mimetica (Australia), he managed the drug discovery and development program for melanocortin-5 receptor antagonists, leading to a compound currently in Phase II human trials.
In his role at CEPTYR (Seattle) he led a multidisciplinary team that developed a preclinical candidate that inhibited protein tyrosine phosphatase 1B for the treatment of diabetes, while at Molecumetics (Seattle) he headed a $2m/yr industrial collaboration on peptidomimetic compounds targeting proteases and GPCRs.
Mark is currently project leader for a Wellcome Trust and NHMRC-funded program that is developing new antibiotics to treat drug resistant pathogens.
He has published more than 30 articles and patents, and is author of 'The Handbook on Syntheses of Amino Acids'.